Search

Background: Bioelectrical impedance analysis (BIA) is widely usedinclinicsandresearchtomeasurebodycomposition.However, the results of BIA validation with reference methods are contradictory, and few data are available on the influence of adiposity on the measurement of body composition by BIA. Objective:The goal was to determine the effects of sex and adiposityonthedifferenceinpercentagebodyfat(%BF)predictedbyBIA compared with dual-energy X-ray absorptiometry (DXA). Design:Atotalof591healthysubjectswererecruitedinNewfoundland and Labrador. %BF was predicted by using BIA and was comparedwiththatmeasuredbyDXA.Methodsagreementwasassessed by Pearson’s correlation and Bland and Altman analysis. Differences in %BF among groups based on sex and adiposity were analyzed by using one-factor analysis of variance with Bonferroni correction. Results: Correlations between BIA and DXA were 0.88 for the whole population, 0.78 for men, and 0.85 for women. The mean %BF determined by BIA (32.89 8.00%) was significantly lower than that measured by DXA (34.72 8.66%). The cutoffs were sex specific. BIA overestimated %BF by 3.03% and 4.40% when %BF was 15% in men and 25% in women, respectively, and underestimated %BF by 4.32% and 2.71% when %BF was 25% in men and 33% in women, respectively. Conclusions: BIA is a good alternative for estimating %BF when subjects are within a normal body fat range. BIA tends to overestimate %BF in lean subjects and underestimate %BF in obese subjects. Am J Clin Nutr 2005;81:74–8.

s / Osteoarthritis and Cartilage 21 (2013) S9–S62 S28 volume of cartilage (2359.16 738.72 mm3 for haplogroup T and 2019.59 577.78 mm3 for haplogroup H) (p 1⁄4 0.009). Conclusions: This work strength the hypothesis that mitochondrial genome is a key factor in the progression of the OA disease. The early identification and classification of patients with haplogroup T and the most common haplogroup H would permit to carry out a more personalized follow-up of the disease. 39 SMAD3 GENE IS ASSOCIATED WITH GENERALIZED OSTEOARTHRITIS E. Aref Eshghi y, Y. Zhang y, D. Hart z, A. Valdes z, A. Furey x, G. Martin x, G. Sun k, P. Rahman k, T.D. Spector z, G. Zhai y,z. yDiscipline of Genetics, Faculty of medicine, Mem. Univ. of Newfoundland, St John's, NL, Canada; zDept. of Twin Res. & Genetic Epidemiology, King's Coll. London, London, United Kingdom; xDiv. of Orthopaedics, Faculty of medicine, Mem. Univ. of Newfoundland, St John's, NL, Canada; kDiscipline of Med., Faculty of medicine, Mem. Univ. of Newfoundland, St John's, NL, Canada Background: Osteoarthritis (OA), the most common form of arthritis in the elderly, causes pain, stiffness, a limited range of motion, joint deformity and disability, and imposes a high economic burden on society. OA is a multifactorial disease with both genetic and environmental factors involved. A newly-described syndrome called Aneurysm-Osteoarthritis Syndrome (AOS) was recently reported. AOS presents with early onset OA in multiple joints, together with aneurysms in the major arteries, and is associated with eight rare mutations in the SMAD3 gene. Because of the similarity with AOS, we hypothesized that SMAD3 is also associated with idiopathic generalized OA (GOA) and tested our hypothesis in a large OA cohort. Methods: Study participants were derived from TwinsUK cohort. Radiographic OA in the hands, knees and hips were assessed using the Kellgren-Lawrence (K/L) scoring system. Joints with a KL rs12913547 (OR1⁄4 1.5, P1⁄4 0.025, CI1⁄4 1.05-2.35) and rs4601989 (OR1⁄4 1.4, P1⁄4 0.041, CI1⁄4 1.01-2.2) with hip OA; and rs6494629 (OR1⁄4 1.44, p1⁄40.025, CI1⁄4 1.04-1.9), rs3825977 (OR1⁄4 0.59, p1⁄4 0.026, CI1⁄4 0.3-0.9), rs16950687 (OR1⁄4 0.6, p1⁄40.035, CI1⁄4 0.40.9) to be associated with hand OA. The associations with individual joint OA are weaker compared with GOA. Conclusion: We demonstrated that variations in the SMAD3 gene are strongly associated with GOA. Further studies are required to reveal the potential mechanism for the association. 40 STRONTIUM RANELATE EFFECT ON KNEE OSTEOARTHRITIS PROGRESSION S. Zaim y, A. Guermazi z,x, F. Roemer z, A. Beaulieu k, S. Hall {, L. Alekseeva , J. Grifka yy, L. Roorda zz, G. Verbruggen xx, R. Wittoek xx, C. Peterfy kk, C. Cooper {{, J.-Y. Reginster ##, H. Genant yyy. y SYNARC, Newark, CA, USA; zRadiology, Boston Univ. Sch. of Med., Boston, MA, USA; x Synarc, San Francisco, CA, USA; kCtr. de Rhumatologie St-Louis, Quebec, QC, Canada; { Emeritius Res., Malvern East, Australia; # Inst. of Rheumatology of RAMS, Moscow, Russian Federation; yyAsklepios Klinikum Bad Abbach, Bad Abbach, Germany; zzAmsterdam Rehabilitation Res. Ctr. Reade, Amsterdam, Netherlands; xxGhent Univ. Hosp., Ghent, Belgium; kk Spire Sci., San Francisco, CA, USA; {{ Southampton Gen. Hosp., MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom; Dept. of Publ. Hlth. Epidemiology and Hlth. Economics of the Univ. of Liege, Liege, Belgium; yyyRadiology, Med. and Orthopaedic Surgery, Univ. of California San Francisco, and Synarc, San Francisco, CA, USA Purpose: In the SEKOIA study, strontium ranelate (SrRan) has demonstrated radiographic structure-modifying activity, by lowering joint space narrowing progression compared to a placebo group. The aim of this analysis was to evaluate the effect of SrRan on knee cartilage and bone in a subset of patients that underwent MRI. Method: SEKOIA is a large international, randomised, placebocontrolled phase III, 3-year study. Included patients were men and women over 50 years of age, with symptomatic primarymedial knee OA (at least 40 on a 100-mm visual analog scale on most days of the previous month, a Kellgren and Lawrence [KL] grade 2 or 3, and joint space width [JSW] of 2.5-5 mm). MRI was performed at inclusion and then annually in a subset of patients from 36 centers. Images were centrally read (Synarc Inc, Hamburg, Germany) and the joint tissue pathology (cartilage morphology, bone edema, subchondral cysts, bone attrition, osteophytes, meniscal damage, synovial effusion.) was evaluated semiquantitatively using the WORMS method. SrRan 1g and SrRan 2g treatment groups were compared to placebo for the change from baseline to the last value, using a general linear regression model adjusted with gender, center and baseline values as covariates. Patients who had a worsening of their score of at least 1 were compared among groups using a chi2 test. Results: MRI ITT included 364 patients. At baseline, the mean age was 62 7years, BMI was 29.9 4.9 kg/m2, and JSW was 3.5 0.8 mm. 65% were KL grade 2 and 67%were female. Therewere no differences among groups at baseline. Over 3 years, progression in WORMS score occurred in less than 45% of the patients for cartilage morphology and less than 20% of the patients for other joint features. There were no differences between treatment groups in mean changes for any parameters. The number of patients with a deterioration of the cartilage morphology was significantly lower in the SrRan 2g group than in the placebo group in the lateral compartment (3.4%, 4 patients vs. 15.7%, 19 patients; p1⁄40.001). No difference was observed in the medial compartment (25% vs 27% in the SrRan 2g and placebo groups, respectively).. For bone features, fewer patients had aworsening of their osteophyte score in the medial compartment in the SrRan 2g group than in the placebo group(12.0%, 14 patients vs. 23.0%, 28 patients; p1⁄40.026), a similar trend was observed in the lateral compartment (p1⁄40.085). No statistically significant differences were observed for the SrRan 1g group compared to placebo (14 patients (11.4%, p1⁄40.324 for lateral cartilage morphology, and 23 patients (18.7), p1⁄40.259) for medial osteophytes). Despite the small number of patients concerned, numerically fewer patients had a worsening of bone attrition score in the SrRan 2g group (2.6% vs. 6.6%) in the medial compartment. Very few meniscal extrusions were observed (less than 6 patients per group) over 3 years. Conclusions: Within the limits of the small number of patients who have a detectable change, strontium ranelate 2g/day reduces cartilage degradation and progression of osteophytes, and tends to decrease bone attrition in patients with knee osteoarthritis. 41 ROLE OF VITAMIN D IN OSTEOARTHRITIS KNEE: A SIX MONTH DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROL TRIAL D. Sanghi y, R.N. Srivastava y, A. Mishra y, S. Natu y, R. Mishra z, S. Agarwal x. yKG Med. Univ., Lucknow, India; z I.T. Coll., Lucknow, India; x SGPGIMS, Lucknow, India Purpose: There is a putative role of vitamin D in osteoarthritis (OA) based on animal, epidemiological and human clinical studies. Short term clinical studies suggest beneficial influence of vitamin D on local changes in the bone which probably accounts for diminished pain experienced in knee OA (KOA). Inadequate sunlight exposure and lower serum levels of 25(OH)D appears to be associated with an increased risk for progression of OA knee. Some chronic analgesic users with OA knee were more likely to be in lower categories of 25(OH) D compared to women with asymptomatic OA. On the basis of above background this study was planned to assess the effect of vitamin D on the progression of disease. Methods: A six month, double blind, randomized and placebo controlled trial of vitamin D, in vitamin D insufficient OA knee subjects (serum 25(OH)D levels

OBJECTIVE To identify novel biomarker(s) for predicting advanced knee OA. METHODS Study participants were derived from the Newfoundland Osteoarthritis Study and the Tasmania Older Adult Cohort Study. All knee OA cases were patients who underwent total knee replacement (TKR) due to primary OA. Metabolic profiling was performed on fasting plasma. Four thousand and eighteen plasma metabolite ratios that were highly correlated with that in SF in our previous study were generated as surrogates for joint metabolism. RESULTS The discovery cohort included 64 TKR cases and 45 controls and the replication cohorts included a cross-sectional cohort of 72 TKR cases and 76 controls and a longitudinal cohort of 158 subjects, of whom 36 underwent TKR during the 10-year follow-up period. We confirmed the previously reported association of the branched chain amino acids to histidine ratio with advanced knee OA (P = 9.3 × 10(-7)) and identified a novel metabolic marker-the lysophosphatidylcholines (lysoPCs) to phosphatidylcholines (PCs) ratio-that was associated with advanced knee OA (P = 1.5 × 10(-7)) after adjustment for age, sex and BMI. When the subjects of the longitudinal cohort were categorized into two groups based on the optimal cut-off of the ratio of 0.09, we found the subjects with the ratio ⩾0.09 were 2.3 times more likely to undergo TKR than those with the ratio